Immatics announced that enrollment in its Phase 3 SUPRAME trial for anzu-cel, a PRAME-targeting cell therapy for advanced melanoma, is on track to complete by year-end. Topline data for progression-free survival is expected in the first half of 2027, followed by a Biologics License Application (BLA) submission to the FDA later that year. The company also reported promising Phase 1 data for other PRAME therapies showing durable anti-tumor activity and manageable safety profiles across multiple cancers. Immatics holds $536.3 million in cash, projecting financial runway into Q4 2028, and is preparing commercial infrastructure for anzu-cel's anticipated launch.
Immatics announced its third quarter 2026 financial results and business update. For readers following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 17:51 WIB: out of 150 priced US health stocks, 76 rose and 58 fell. Notable movers include Revvity Inc (RVTY) at USD 163.35 with a 1-day change of +1.64%, LifeStance Health Group Inc. (LFST) at USD 14.81 up 1.44%, and Moderna, Inc. (MRNA) at USD 272.82 with a 1.42% increase.
The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...
Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...
PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...
Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...
Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...
